<DOC>
	<DOCNO>NCT01473056</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics anti-viral activity JTK-853 hepatitis C virus genotype 1 infected subject base reduction viral load ( HCV RNA level ) baseline end treatment , follow genotypic resistance monitor one year study drug treatment .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacokinetics &amp; Antiviral Activity JTK-853 Hepatitis C Virus Genotype 1 Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>1 . Males female infect chronic hepatitis C virus ( HCV ) infection genotype 1a 1b 2 . Subjects viral load ( HCV RNA level ) â‰¥50,000 IU/mL 3 . Subjects body mass index ( BMI ) 18.036.0 kg/m2 ( inclusive ) 1 . Subjects previously receive direct act antiHCV agent 2 . Subjects previously receive pegylated interferon/ribavirin duration two week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>JTK-853</keyword>
</DOC>